Clinical iron deficiency disturbs normal human responses to hypoxia

Journal of Clinical Investigation

Volumn 126, Issue 6, 2016, Pages 2139-2150

  Frise, Matthew C ^a   Cheng, Hung Yuan ^a   Nickol, Annabel H ^b   Curtis, M Kate ^a   Pollard, Karen A ^a   Roberts, David J ^a   Ratcliffe, Peter J ^c   Dorrington, Keith L ^a   Robbins, Peter A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEPCIDIN; INTERLEUKIN 6; IRON; OXYHEMOGLOBIN; EPO PROTEIN, HUMAN; HAMP PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; HYPOXIA; HYPOXIA-INDUCED PULMONARY HYPERTENSION; INTERVENTION STUDY; IRON CHELATION; IRON DEFICIENCY; IRON THERAPY; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY SYSTOLIC PRESSURE; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; ARTERIAL PRESSURE; BLOOD; BREATHING; CASE CONTROL STUDY; COMPLICATION; DEFICIENCY; DIAGNOSTIC IMAGING; HEART OUTPUT; HYPERTENSION, PULMONARY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY ARTERY; SIGNAL TRANSDUCTION;

ADULT; ARTERIAL PRESSURE; CARDIAC OUTPUT; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; ERYTHROPOIETIN; FEMALE; HEPCIDINS; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA; INTERLEUKIN-6; IRON; MALE; MIDDLE AGED; OXYHEMOGLOBINS; PROSPECTIVE STUDIES; PULMONARY ARTERY; RESPIRATION; SIGNAL TRANSDUCTION;

EID: 84974626874     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85715     Document Type: Article

References (125)

1. Kaelin WG Jr. Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402.
2. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365(6):537-547.
3. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230-1237.
4. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996;271(30):17771-17778.
5. Forsythe JA, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-4613.
6. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177-185.
7. Tan Q, et al. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem. 2013;288(24):17134-17144.
8. Ghosh MC, et al. Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2α. Cell Metab. 2013;17(2):271-281.
9. Yu AY, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J Clin Invest. 1999;103(5):691-696.
10. Brusselmans K, et al. Heterozygous deficiency of hypoxia-inducible factor-2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest. 2003;111(10):1519-1527.
11. Bishop T, et al. Carotid body hyperplasia and enhanced ventilatory responses to hypoxia in mice with heterozygous deficiency of PHD2. J Physiol. 2013;591(14):3565-3577.
12. Aragones J, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008;40(2):170-180.
13. Hodson EJ, et al. Regulation of ventilatory sensitivity and carotid body proliferation in hypoxia by the PHD2/HIF-2 pathway. J Physiol. 2016;594(5):1179-1195.
14. Percy MJ, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358(2):162-168.
15. Ladroue C, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008;359(25):2685-2692.
16. Formenti F, et al. Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2α gain-of-function mutation. FASEB J. 2011;25(6):2001-2011.
17. Formenti F, et al. Regulation of human metabolism by hypoxia-inducible factor. Proc Natl Acad Sci U S A. 2010;107(28):12722-12727.
18. Smith TG, et al. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 2006;3(7):e290.
19. Petousi N, et al. Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia. J Appl Physiol (1985). 2014;116(7):893-904.
20. Lorenzo FR, et al. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet. 2014;46(9):951-956.
21. Beall CM, et al. Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A. 2010;107(25):11459-11464.
22. Bishop T, Ratcliffe PJ. HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ Res. 2015;117(1):65-79.
23. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337-1340.
24. Epstein AC, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43-54.
25. Ivan M, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468.
26. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15(20):2675-2686.
27. Hewitson KS, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002;277(29):26351-26355.
28. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002;16(12):1466-1471.
29. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol. 2008;4(3):152-156.
30. Clifton IJ, McDonough MA, Ehrismann D, Kershaw NJ, Granatino N, Schofield CJ. Structural studies on 2-oxoglutarate oxygenases and related double-stranded β-helix fold proteins. J Inorg Biochem. 2006;100(4):644-669.
31. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5(5):343-354.
32. Mole DR. Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal. 2010;12(4):445-458.
33. Maxwell P, Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther. 2004;3(1):29-35.
34. Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL. Normoxic stabilization of hypoxia-inducible factor-1α by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res. 2006;66(5):2600-2607.
35. Pan Y, et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol. 2007;27(3):912-925.
36. Eckard J, et al. Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis. Cancer Cell Int. 2010;10:28.
37. Nandal A, et al. Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2. Cell Metab. 2011;14(5):647-657.
38. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med. 1982;306(25):1520-1528.
39. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet. 2007;370(9586):511-520.
40. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754-4761.
41. Thomas DW, et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161(5):639-648.
42. Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128.
43. World Health Organisation. Nutrition: Micronutrient deficiencies. WHO Web site. http://www.who.int/nutrition/topics/ida/en/. Accessed March 29, 2016.
44. Smith TG, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009;302(13):1444-1450.
45. Smith TG, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008;586(24):5999-6005.
46. Westcott RN, Fowler NO, Scott RC, Hauenstein VD, McGuire J. Anoxia and human pulmonary vascular resistance. J Clin Invest. 1951;30(9):957-970.
47. Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol (1985). 2002;92(6):2501-2507.
48. Talbot NP, Balanos GM, Dorrington KL, Robbins PA. Two temporal components within the human pulmonary vascular response to approximately 2 h of isocapnic hypoxia. J Appl Physiol (1985). 2005;98(3):1125-1139.
49. Allen J, et al. Measurement of soluble transferrin receptor in serum of healthy adults. Clin Chem. 1998;44(1):35-39.
50. Soon E, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax. 2011;66(4):326-332.
51. Ruiter G, et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology. 2014;53(2):285-292.
52. Ruiter G, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011;37(6):1386-1391.
53. Rhodes CJ, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011;58(3):300-309.
54. Klip IT, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.
55. Ponikowski P, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-668.
56. Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-2448.
57. Jankowska EA, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35(36):2468-2476.
58. Nickol AH, et al. A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease. BMJ Open. 2015;5(7):e007911.
59. Viethen T, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol. 2014;175(2):233-239.
60. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82(12):3610-3615.
61. Ren X, Dorrington KL, Maxwell PH, Robbins PA. Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. J Appl Physiol (1985). 2000;89(2):680-686.
62. Talbot NP, et al. Contrasting effects of ascorbate and iron on the pulmonary vascular response to hypoxia in humans. Physiol Rep. 2014;2(12):e12220.
63. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97(3):792-798.
64. Zhu BZ, Har-El R, Kitrossky N, Chevion M. New modes of action of desferrioxamine: scavenging of semiquinone radical and stimulation of hydrolysis of tetrachlorohydroquinone. Free Radic Biol Med. 1998;24(2):360-369.
65. Weir EK, Lopez-Barneo J, Buckler KJ, Archer SL. Acute oxygen-sensing mechanisms. N Engl J Med. 2005;353(19):2042-2055.
66. Deem S, Swenson ER, Alberts MK, Hedges RG, Bishop MJ. Red-blood-cell augmentation of hypoxic pulmonary vasoconstriction: hematocrit dependence and the importance of nitric oxide. Am J Respir Crit Care Med. 1998;157(4 pt 1):1181-1186.
67. Kerbaul F, et al. Prevention of hemodilution-induced inhibition of hypoxic pulmonary vasoconstriction by N-acetylcysteine in dogs. Anesth Analg. 2004;99(2):547-551.
68. Winslow RM, et al. Effects of hemodilution on O2 transport in high-altitude polycythemia. J Appl Physiol (1985). 1985;59(5):1495-1502.
69. Manier G, Guenard H, Castaing Y, Varene N, Vargas E. Pulmonary gas exchange in Andean natives with excessive polycythemia - effect of hemodilution. J Appl Physiol (1985). 1988;65(5):2107-2117.
70. Weisse AB, Moschos CB, Frank MJ, Levinson GE, Cannilla JE, Regan TJ. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med. 1975;58(1):92-98.
71. Naeije R, Dedobbeleer C. Pulmonary hypertension and the right ventricle in hypoxia. Exp Physiol. 2013;98(8):1247-1256.
72. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3(1):12-33.
73. Morrell NW, Nijran KS, Biggs T, Seed WA. Magnitude and time course of acute hypoxic pulmonary vasoconstriction in man. Respir Physiol. 1995;100(3):271-281.
74. Dorrington KL, Clar C, Young JD, Jonas M, Tansley JG, Robbins PA. Time course of the human pulmonary vascular response to 8 hours of isocapnic hypoxia. Am J Physiol. 1997;273(3 pt 2):H1126-H1134.
75. Frise MC, Robbins PA. Iron, oxygen, and the pulmonary circulation. J Appl Physiol (1985). 2015;119(12):1421-1431.
76. Shimoda LA, Laurie SS. HIF and pulmonary vascular responses to hypoxia. J Appl Physiol (1985). 2014;116(7):867-874.
77. Groves BM, et al. Operation Everest II: elevated high-altitude pulmonary resistance unresponsive to oxygen. J Appl Physiol (1985). 1987;63(2):521-530.
78. Cotroneo E, et al. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. Circ Res. 2015;116(10):1680-1690.
79. Herigstad M, Robbins PA. Pulmonary vascular response to air-breathing exercise in humans following an 8-h exposure to hypoxia. Respir Physiol Neurobiol. 2009;169(1):11-15.
80. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-756.
81. Yoshida K, et al. Color Doppler evaluation of valvular regurgitation in normal subjects. Circulation. 1988;78(4):840-847.
82. Jobic Y, et al. Doppler echocardiographic evaluation of valve regurgitation in healthy volunteers. Br Heart J. 1993;69(2):109-113.
83. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104(23):2797-2802.
84. Chan KL, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol. 1987;9(3):549-554.
85. Currie PJ, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6(4):750-756.
86. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984;70(4):657-662.
87. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6(2):359-365.
88. Stevenson JG. Comparison of several noninvasive methods for estimation of pulmonary artery pressure. J Am Soc Echocardiogr. 1989;2(3):157-171.
89. Allemann Y, et al. Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol. 2000;279(4):H2013-H2016.
90. Okura H, et al. Prevalence and correlates of physiological valvular regurgitation in healthy subjects. Circ J. 2011;75(11):2699-2704.
91. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663-2670.
92. Maxwell PH, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 1993;44(5):1149-1162.
93. Wenger RH, Hoogewijs D. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. Am J Physiol Renal Physiol. 2010;298(6):F1287-F1296.
94. Erslev AJ, Caro J, Besarab A. Why the kidney? Nephron. 1985;41(3):213-216.
95. Gassmann M, Muckenthaler MU. Adaptation of iron requirement to hypoxic conditions at high altitude. J Appl Physiol (1985). 2015;119(12):1432-1440.
96. de Klerk G, Rosengarten PC, Vet RJ, Goudsmit R. Serum erythropoietin (EST) titers in anemia. Blood. 1981;58(6):1164-1170.
97. Ward HP, Kurnick JE, Pisarczyk MJ. Serum level of erythropoietin in anemias associated with chronic infection, malignancy, and primary hematopoietic disease. J Clin Invest. 1971;50(2):332-335.
98. Erslev AJ, Caro J. Erythropoietin titers in response to anemia or hypoxia. Blood Cells. 1987;13(1-2):207-216.
99. Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
100. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337-2343.
101. Nicolas G, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-1044.
102. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204-3209.
103. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122(12):4635-4644.
104. Talbot NP, et al. Regulation of hepcidin expression at high altitude. Blood. 2012;119(3):857-860.
105. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
106. Abakay O, et al. Relationship between hepcidin levels and periodic limb movement disorder in patients with obstructive sleep apnea syndrome. Sleep Breath. 2015;19(2):459-466.
107. Liu Y, Yu Z, Hua D, Chen Y, Zheng S, Wang L. Association of serum hepcidin levels with the presence and severity of obstructive sleep apnea syndrome. Med Sci Monit. 2015;21:27-31.
108. Lundgrin EL, et al. Plasma hepcidin of Ethiopian highlanders with steady-state hypoxia. Blood. 2013;122(11):1989-1991.
109. Naeije R, Vanderpool R. Pulmonary hypertension and chronic mountain sickness. High Alt Med Biol. 2013;14(2):117-125.
110. Talbot NP, et al. Suppression of plasma hepcidin by venesection during steady-state hypoxia. Blood. 2016;127(9):1206-1207.
111. Beall CM, et al. Hemoglobin concentration of high-altitude Tibetans and Bolivian Aymara. Am J Phys Anthropol. 1998;106(3):385-400.
112. Groves BM, et al. Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m. J Appl Physiol (1985). 1993;74(1):312-318.
113. Zhuang J, et al. Hypoxic ventilatory responsiveness in Tibetan compared with Han residents of 3,658 m. J Appl Physiol (1985). 1993;74(1):303-311.
114. Simonson TS. Altitude adaptation: a glimpse through various lenses. High Alt Med Biol. 2015;16(2):125-137.
115. Yi X, et al. Sequencing of 50 human exomes reveals adaptation to high altitude. Science. 2010;329(5987):75-78.
116. Bigham A, et al. Identifying signatures of natural selection in Tibetan and Andean populations using dense genome scan data. PLoS Genet. 2010;6(9):e1001116.
117. Simonson TS, et al. Genetic evidence for high-altitude adaptation in Tibet. Science. 2010;329(5987):72-75.
118. Kjaergaard J, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99(8):1146-1150.
119. Seeger W, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 suppl):D109-D116.
120. Smith GA, Fisher SA, Doree C, Di Angelantonio E, Roberts DJ. Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. Cochrane Database Syst Rev. 2014;7:CD009532.
121. Turner BE, Hodkinson PD, Timperley AC, Smith TG. Pulmonary artery pressure response to simulated air travel in a hypobaric chamber. Aerosp Med Hum Perform. 2015;86(6):529-534.
122. Balanos GM, Pugh K, Frise MC, Dorrington KL. Exaggerated pulmonary vascular response to acute hypoxia in older men. Exp Physiol. 2015;100(10):1187-1198.
123. Fatemian M, et al. Determinants of ventilation and pulmonary artery pressure during early acclimatization to hypoxia in humans. J Physiol. 2016;594(5):1197-1213.
124. Howard LS, et al. Chamber for controlling end-tidal gas tensions over sustained periods in humans. J Appl Physiol (1985). 1995;78(3):1088-1091.
125. Bihari S, et al. Bolus intravenous 0.9% saline, but not 4% albumin or 5% glucose, causes interstitial pulmonary edema in healthy subjects. J Appl Physiol (1985). 2015;119(7):783-792.